Alvotech (NASDAQ:ALVO) Shares Down 7.6% – What’s Next?

Shares of Alvotech (NASDAQ:ALVO) dropped 7.6% during mid-day trading on Friday. The stock traded as low as $4.36 and last traded at $4.3150. Approximately 108,178 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 773,409 shares. The stock had previously closed at $4.67.

Recent Alvotech Headlines

Investors following ALVO have been watching these headlines:

• Positive Sentiment: Alvotech forecast 2026 revenue of $650 million–$700 million, broadly around or above the $652.5 million consensus at the midpoint, and EBITDA of $180 million–$220 million. Management said it expects the fourth quarter to be the strongest in company history. Article: Alvotech targets $650M-$700M revenue and $180M-$220M EBITDA
• Neutral Sentiment: The earnings call highlighted growth opportunities alongside business risks; the available article summary did not specify further details. Article: Alvotech Earnings Call Highlights Growth and Risks
• Negative Sentiment: Q3 revenue of $111.6 million fell short of the $125.2 million analyst estimate. Alvotech posted a loss of $0.03 per share; while that beat one reported consensus estimate of a $0.04 loss, it missed Zacks’ estimate of a $0.01 loss. The revenue miss and mixed earnings comparisons could pressure the shares. Article: Alvotech Reports Q3 Loss, Lags Revenue Estimates

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Zacks Research downgraded shares of Alvotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Wall Street Zen raised Alvotech from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Evercore assumed coverage on Alvotech in a research report on Friday, August 14th. They set an “outperform” rating for the company. Finally, Jefferies Financial Group started coverage on Alvotech in a research note on Tuesday, November 10th. They issued a “buy” rating and a $9.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.40.

Alvotech Stock Performance

The stock’s fifty day moving average price is $5.23 and its 200-day moving average price is $4.20. The company has a market capitalization of $1.26 billion, a P/E ratio of -5.11 and a beta of 0.24.

Alvotech (NASDAQ:ALVO) last announced its quarterly earnings results on Wednesday, November 11th. The company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $111.60 million for the quarter, compared to analyst estimates of $123.45 million. On average, research analysts predict that Alvotech will post -0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Alvotech

A number of large investors have recently added to or reduced their stakes in ALVO. Citadel Advisors LLC bought a new position in Alvotech during the second quarter worth $6,376,000. Royce & Associates LP bought a new position in shares of Alvotech in the third quarter valued at about $3,817,000. Marshall Wace LLP bought a new position in shares of Alvotech in the third quarter valued at about $2,326,000. Ulland Investment Advisors LLC lifted its stake in shares of Alvotech by 5.0% during the 3rd quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock worth $667,000 after buying an additional 5,500 shares during the last quarter. Finally, State Street Corp acquired a new stake in shares of Alvotech during the 3rd quarter worth about $594,000.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.